The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Fluticasone/formoterol (Flutiform®) has been accepted for use in the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate:
- for patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist
- or for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist
This product has already been accepted for use in adults and adolescents aged 12 years and above on the same basis.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - May 2019||Drug Safety Update - June 2019 »|